Anders Mikael Strom

Dr. Anders Mikael Strom

Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
JHJohan Hartman
Johan Hartman
KEKarin Edvardsson
Karin Edvardsson
KLKarolina Lindberg
Karolina Lindberg
CZChunyan Zhao
Chunyan Zhao
Cecilia WilliamsCecilia Williams
Cecilia Williams
JGJan-Åke Gustafsson
Jan-Åke Gustafsson
Estrogen receptor β (ERβ) is the predominant ER in the colorectal epithelium. Compared with normal colon tissue, ERβ expression is reduced in colorectal cancer. Our hypothesis is that ERβ inhibits proliferation of colon cancer cells. Hence, the aim of this study has been to investigate the molecular function of ERβ in colon cancer cells, focusing on cell cycle regulation. SW480 colon cancer cells have been lentivirus transduced with ERβ expression construct with or without mutated DNA-binding domain or an empty control vector. Expression of ERβ resulted in inhibition of proliferation and G1 phase cell cycle arrest and this effect was dependent on a functional DNA-binding region. c-Myc is overexpressed in an overwhelming majority of colorectal tumors. By Western blot and real-time PCR, we found c-Myc to be down-regulated in the ERβ-expressing cells. Furthermore, the c-Myc target gene p21(Waf1/Cip1) was induced and Cdc25A was reduced by ERβ at the transcriptional level. The second cdk2-inhibitor, p27Kip1, was induced by ERβ, but this regulation occurred at the posttranscriptional level, probably through ERβ-mediated repression of the F-box protein p45Skp2. Expression of the ERβ-variant with mutated DNA binding domain resulted in completely different cell cycle gene regulation. We performed in vivo studies with SW480 cells ± ERβ transplanted into severe combined immunodeficient/beige mice; after three weeks of ERβ-expression, a 70% reduction of tumor volume was seen. Our results show that ERβ inhibits proliferation as well as colon cancer xenograft growth, probably as a consequence of ERβ-mediated inhibition of cell-cycle pathways. Furthermore, this ERβ-mediated cell cycle repression is dependent on functional ERE binding. [Cancer Res 2009;69(15):6100–6]

1 December 2012 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
PDPrasenjit Dey
Prasenjit Dey
PJPhilip Jonsson
Philip Jonsson
JHJohan Hartman
Johan Hartman
Cecilia WilliamsCecilia Williams
Cecilia Williams
Anders Mikael StromAnders Mikael Strom
Anders Mikael Strom
JGJan-Åke Gustafsson
Jan-Åke Gustafsson
The estrogen receptor (ER)β1 is successively lost during cancer progression, whereas its splice variant, ERβ2, is expressed in advanced prostate cancer. The latter form of cancer often metastasizes to bone, and we wanted to investigate whether the loss of ERβ1 and/or the expression of ERβ2 affect such signaling pathways in prostate cancer. Using PC3 and 22Rv1 prostate cancer cell lines that stably express ERβ1 or ERβ2, we found that the ERβ variants differentially regulate genes known to affect tumor behavior. We found that ERβ1 repressed the expression of the bone metastasis regulator Runx2 in PC3 cells. By contrast, RUNX2 expression was up-regulated at the mRNA level by ERβ2 in PC3 cells, whereas Slug was up-regulated by ERβ2 in both PC3 and 22Rv1 cells. In addition, the expression of Twist1, a factor whose expression strongly correlates with high Gleason grade prostate carcinoma, was increased by ERβ2. In agreement with the increased Twist1 expression, we found increased expression of Dickkopf homolog 1; Dickkopf homolog 1 is a factor that has been shown to increase the RANK ligand/osteoprotegerin ratio and enhance osteoclastogenesis, indicating that the expression of ERβ2 can cause osteolytic cancer. Furthermore, we found that only ERβ1 inhibited proliferation, whereas ERβ2 increased proliferation. The expression of the proliferation markers Cyclin E, c-Myc, and p45Skp2 was differentially affected by ERβ1 and ERβ2 expression. In addition, nuclear β-catenin protein and its mRNA levels were reduced by ERβ1 expression. In conclusion, we found that ERβ1 inhibited proliferation and factors known to be involved in bone metastasis, whereas ERβ2 increased proliferation and up-regulated factors involved in bone metastasis. Thus, in prostate cancer cells, ERβ2 has oncogenic abilities that are in strong contrast to the tumor-suppressing effects of ERβ1.

26 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PDPrasenjit Dey
Prasenjit Dey
LVLaura Alejandra Velazquez-Villegas
Laura Alejandra Velazquez-Villegas
MFMichelle Faria
Michelle Faria
ATAnthony Turner
Anthony Turner
PJPhilp Jonsson
Philp Jonsson
Anders Mikael StromAnders Mikael Strom
Anders Mikael Strom
The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant prostate cancer and has been shown to correlate with decreased overall survival. Genome-wide expression analysis after ERβ2 expression in prostate cancer cells revealed that hypoxia was an overrepresented theme. Here we show that ERβ2 interacts with and stabilizes HIF-1α protein in normoxia, thereby inducing a hypoxic gene expression signature. HIF-1α is known to stimulate metastasis by increasing expression of Twist1 and increasing vascularization by directly activating VEGF expression. We found that ERβ2 interacts with HIF-1α and piggybacks to the HIF-1α response element present on the proximal Twist1 and VEGF promoters. These findings suggest that at least part of the oncogenic effects of ERβ2 is mediated by HIF-1α and that targeting of this ERβ2 – HIF-1α interaction may be a strategy to treat prostate cancer.

15 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSurendra Chaurasiya
Surendra Chaurasiya
SWScott Widmann
Scott Widmann
CBCindy Botero
Cindy Botero
CLChin-Yo Lin
Chin-Yo Lin
JGJan-Åke Gustafsson
Jan-Åke Gustafsson
Anders Mikael StromAnders Mikael Strom
Anders Mikael Strom
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in human and rodent prostate epithelium, stroma, immune cells and endothelium of the blood vessels. In the prostates of mice with inactivated ERβ, mutant phenotypes include epithelial hyperplasia and increased expression of androgen receptor (AR)-regulated genes, most of which are also upregulated in prostate cancer (PCa). ERβ is expressed in both basal and luminal cells in the prostate while AR is expressed in luminal but not in the basal cell layer which harbors the prostate stem cells. To investigate the mechanisms of action of ERβ and its potential cross-talk with AR, we used RNA-seq to study the effects of estradiol or the synthetic ligand, LY3201, in AR-positive LNCaP PCa cells which had been engineered to express ERβ. Transcriptomic analysis indicated relatively few changes in gene expression with ERβ overexpression, but robust responses following ligand treatments. There is significant overlap of responsive genes between the two ligands, estradiol and LY3201 as well as ligand-specific alterations. Gene set analysis of down-regulated genes identified an enrichment of androgen-responsive genes, such as FKBP5, CAMKK2, and TBC1D4. Consistently, AR transcript, protein levels, and transcriptional activity were down-regulated following ERβ activation. In agreement with this, we find that the phosphorylation of the CAMKK2 target, AMPK, was repressed by ligand-activated ERβ. These findings suggest that ERβ-mediated signaling pathways are involved in the negative regulation of AR expression and activity, thus supporting a tumor suppressive role for ERβ in PCa.

5 November 2009 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
JHJohan Hartman
Johan Hartman
Eric LamEric Lam
Eric Lam
JGJan-Ake Gustafsson
Jan-Ake Gustafsson
Anders Mikael StromAnders Mikael Strom
Anders Mikael Strom
Introduction: Hes-6 is a member of the basic helix-loop-helix (bHLH) family of transcription factors, and its overexpression has been reported in metastatic cancers of different origins. Hes-6 has been described as an inhibitor of Hes-1 during neuronal development, although its function in cancer is not known. In this study, we investigated the function of Hes-6 in breast cancer and tested the hypothesis that Hes-6 enhances breast cancer cell proliferation and is regulated by estrogen. Methods: To investigate the function of Hes-6, T47D cells stably expressing Hes-6 were generated by lentiviral transduction, and conversely, siRNA also was used to knock down Hes-6 expression in breast cancer cells. The Hes-6-expressing T47D cells were transplanted into immunodeficient mice to study effects on tumor growth. Results: We found that Hes-6 expression was significantly higher in the high-grade, estrogen receptor (ER)α-negative SKBR3 and MDA-MB-231 cells compared with the ERα-positive, non-metastasizing T47D and MCF-7 breast carcinoma cells. Moreover, the level of Hes-6 mRNA was 28 times higher in breast cancer samples compared with normal breast samples. In Hes-6-expressing T47D cells, Hes-6 ectopic expression was shown to stimulate cell proliferation in vitro as well as breast tumor growth in xenografts. Moreover, expression of Hes-6 resulted in induction of E2F-1, a crucial target gene for the transcriptional repressor Hes-1. Consistently, silencing of Hes-6 by siRNA resulted in downregulation of E2F-1 expression, whereas estrogen treatment caused induction of Hes-6 and downstream targets hASH-1 and E2F-1 in MCF-7 cells. Conclusions: Together, the data suggest that Hes-6 is a potential oncogene overexpressed in breast cancer, with a tumor-promoting and proliferative function. Furthermore, Hes-6 is a novel estrogen-regulated gene in breast cancer cells. An understanding of the role and regulation of Hes-6 could provide insights into estrogen signaling and endocrine resistance in breast cancer and, hence, could be important for the development of novel anticancer drugs.

20 November 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MFMichelle Faria
Michelle Faria
PSPeter Shepherd
Peter Shepherd
YPYinghong Pan
Yinghong Pan
SCSujash S. Chatterjee
Sujash S. Chatterjee
NNNora Navone
Nora Navone
Anders Mikael StromAnders Mikael Strom
Anders Mikael Strom
Oncotarget | https://doi.org/10.18632/oncotarget.26345 Michelle Faria, Peter Shepherd, Yinghong Pan, Sujash S. Chatterjee, Nora Navone, Jan-Åke Gustafsson, Anders Strom The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling